TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01421771

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antihypertensive Agents
Description: Study formulary consists of ACE/ARB, Beta Adrenergic Blocker, Calcium Channel Blocker, vasodilators, peripheral alpha antagonist and central alpha agonist.~ACE I or ARB is first line, the order of addition of subsequent medications is per the discretion of the investigator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antihypertensive Agents
Description: Study formulary consists of ACE/ARB, Beta Adrenergic Blocker, Calcium Channel Blocker, vasodilators, peripheral alpha antagonist and central alpha agonist.~ACE I or ARB is first line, the order of addition of subsequent medications is per the discretion of the investigator

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry weight Challenge
Description: Reduce the estimated dry weight of the patient's progressively over 2 -week intervals until the dry weight challenge is no longer tolerated or the patient is at BP goal

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dry weight Challenge
Description: Reduce the estimated dry weight of the patient's progressively over 2 -week intervals until the dry weight challenge is no longer tolerated or the patient is at BP goal

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Extend dialysis treatment time and re-challenge estimated dry weight
Description: Extend dialysis treatment time and re-challenge estimated dry weight

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Extend dialysis treatment time and re-challenge estimated dry weight
Description: Extend dialysis treatment time and re-challenge estimated dry weight
Study: NCT01218828

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LVEDP -Based hydration strategy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard hydration
Study: NCT02863159

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tecnis Multifocal 1-Piece IOL
Description: +2.75D (ZKB00), +3.25D (ZKB00), +4.00D (ZMB00)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tecnis Multifocal 1-Piece IOL
Description: +2.75D (ZKB00), +3.25D (ZKB00), +4.00D (ZMB00)
Study: NCT06191536

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Study: NCT04253964

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QLQ-C30 Global Health/Quality of Life Questionnaire
Description: 30 item questionnaire - Functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, and nausea and vomiting), global health status and quality of life scale, also several single-item symptom measures

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COPD Assessment Test and modified Medical Research Council Dyspnea Patient Reported Outcomes
Description: Dyspnea scale scores in patients with respiratory disease (particularly COPD) to establish baseline functional dyspnea burden (taken pre-study at Week 0 and Post Treatment at week 13)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COPD Assessment Test and modified Medical Research Council Dyspnea Patient Reported Outcomes
Description: Dyspnea scale scores in patients with respiratory disease (particularly COPD) to establish baseline functional dyspnea burden (taken pre-study at Week 0 and Post Treatment at week 13)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: FOR PARTICIPANTS IN EITHER ARM with nonsquamous subtype, predictive biomarker PD-L1 less than 50%: Pemetrexed 500 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: FOR PARTICIPANTS IN EITHER ARM with nonsquamous subtype, predictive biomarker PD-L1 less than 50%: Pemetrexed 500 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles.
Study: NCT00898378

Intervention type: GENETIC
Intervention: gene expression analysis
Description: gene expression analysis

Intervention type: GENETIC
Intervention: gene expression analysis
Description: gene expression analysis

Intervention type: GENETIC
Intervention: gene expression analysis
Description: gene expression analysis

Intervention type: GENETIC
Intervention: polymerase chain reaction
Description: polymerase chain reaction

Intervention type: GENETIC
Intervention: polymerase chain reaction
Description: polymerase chain reaction
Study: NCT06191536

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor exercises
Study: NCT03885037

Intervention type: DRUG
Intervention: Infliximab [infliximab biosimilar 3]
Description: \<Rheumatoid arthritis\> The usual dose is 3 mg as Infliximab \[Infliximab Biosimilar 3\] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter. After a dose at Week 6 is given, the dose may be increased or the dosing interval may be reduced for patients who have an incomplete response or reduced effects. These adjustments should be made in a stepwise manner. The maximum dose is 10 mg for every kg of body weight at the dosing interval of 8 weeks and 6 mg for every kg of body weight at a reduced dosing interval. The minimum dosing interval is 4 weeks. This drug should be given in combination with methotrexate.
Study: NCT01496196

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tranexamic acid
Description: 500 mg/5 ml 3-4 times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tranexamic acid
Description: 500 mg/5 ml 3-4 times a day
Study: NCT02039700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]lesinurad (100 μg per 10 mL)
Study: NCT00898378

Intervention type: GENETIC
Intervention: polymerase chain reaction
Description: polymerase chain reaction

Intervention type: GENETIC
Intervention: polymorphism analysis
Description: polymorphism analysis

Intervention type: GENETIC
Intervention: polymorphism analysis
Description: polymorphism analysis

Intervention type: GENETIC
Intervention: polymorphism analysis
Description: polymorphism analysis

Intervention type: GENETIC
Intervention: protein expression analysis
Description: protein expression analysis

Intervention type: GENETIC
Intervention: protein expression analysis
Description: protein expression analysis

Intervention type: GENETIC
Intervention: protein expression analysis
Description: protein expression analysis

Intervention type: GENETIC
Intervention: proteomic profiling
Description: proteomic profiling

Intervention type: GENETIC
Intervention: proteomic profiling
Description: proteomic profiling

Intervention type: GENETIC
Intervention: proteomic profiling
Description: proteomic profiling

Intervention type: OTHER
Intervention: gas chromatography
Description: gas chromatography

Intervention type: OTHER
Intervention: gas chromatography
Description: gas chromatography
Study: NCT01680601

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Description: RIPC will be performed by 3 cycles of 5 minute leg ischaemia induced by inflation of a blood pressure cuff to 40 mmHg above the patient's systolic pressure. This protocol will be performed at two phases: 24 hours before surgery and during anaesthesia immediately prior to surgery.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03605992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based Rehab
Description: This intervention will have the duration of 12 weeks, with a total of 60 sessions: 2 supervised and 58 at home (to complete five exercise's sessions for week).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CentreRehab
Description: This intervention will last 12 weeks, with a total of 60 sessions: 24 supervised and 36 at home (to complete five exercise's sessions for week).
Study: NCT01222364

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Cord Clamping
Description: Immediate clamping (\<5 seconds) of the umbilical cord after delivery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed Cord Clamping
Description: Clamping of the umbilical cord at 30-45 seconds after birth.
Study: NCT00380796

Intervention type: DRUG
Intervention: Collection of safety data for Cohort 1
Description: Twice-yearly collection of information about cancer incidence and cause of death among patients who participated in clinical trials of infliximab in the treatment of COPD. The follow-up period is 5 years.
Study: NCT02000115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portico transcatheter aortic valve
Description: St. Jude Medical transcatheter Portico aortic valve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portico transcatheter aortic valve
Description: St. Jude Medical transcatheter Portico aortic valve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portico transcatheter aortic valve
Description: St. Jude Medical transcatheter Portico aortic valve

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available transcatheter aortic valve
Description: Commercially available transcatheter aortic valve
Study: NCT00093730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-59926
Study: NCT03043898

Intervention type: OTHER
Intervention: Lung sound transmission measurement
Description: Sound at chest wall is recorded using a sensor array during the bronchoscopy procedure, while a sound is played down the working channel of the bronchoscope.

Intervention type: OTHER
Intervention: Lung sound transmission measurement
Description: Sound at chest wall is recorded using a sensor array during the bronchoscopy procedure, while a sound is played down the working channel of the bronchoscope.

Intervention type: OTHER
Intervention: Lung sound recording
Description: Lung sounds are recorded using a sensor array.

Intervention type: OTHER
Intervention: Lung sound recording
Description: Lung sounds are recorded using a sensor array.
Study: NCT02995187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate tablet
Description: Apatinib 500 mg in tablet once daily
Study: NCT01689155

Intervention type: BIOLOGICAL
Intervention: Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, Intramuscular
Study: NCT03644043

Intervention type: DEVICE
Intervention: EEG scan
Description: WAVi EEG and evoked potential platform. Participants will be scanned using the ElectroCap (FDA Class II) and/or the WAVi Headset with the WAVi Co EEG P300 system, along with the structured clinical interviews and assessments for the various ailments or baseline screenings
Study: NCT04664881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartHeart Device
Description: A body-worn device that allows an individual to immediately transmit a 12-lead ECG from anywhere and anytime, using a smartphone application to a physician's office, hospital or monitoring center where designated on-call staff interpret the ECG and make recommendations.
Study: NCT03945058

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TVS
Description: Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour daily for 4 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TVS
Description: Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour daily for 4 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the earl lobule. Stimulator will be applied continuously for 1 hour daily for 4 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SHAM
Description: Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the earl lobule. Stimulator will be applied continuously for 1 hour daily for 4 weeks.
Study: NCT01160640

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: ceftrixone 250mg IM single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ceftriaxone
Description: ceftrixone 250mg IM single dose
Study: NCT00898378

Intervention type: OTHER
Intervention: gas chromatography
Description: gas chromatography

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: laboratory biomarker analysis

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: laboratory biomarker analysis

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: laboratory biomarker analysis

Intervention type: OTHER
Intervention: liquid chromatography
Description: liquid chromatography

Intervention type: OTHER
Intervention: liquid chromatography
Description: liquid chromatography

Intervention type: OTHER
Intervention: liquid chromatography
Description: liquid chromatography

Intervention type: OTHER
Intervention: mass spectrometry
Description: mass spectrometry

Intervention type: OTHER
Intervention: mass spectrometry
Description: mass spectrometry

Intervention type: OTHER
Intervention: mass spectrometry
Description: mass spectrometry

Intervention type: OTHER
Intervention: questionnaire administration
Description: questionnaire administration

Intervention type: OTHER
Intervention: questionnaire administration
Description: questionnaire administration

Intervention type: OTHER
Intervention: questionnaire administration
Description: questionnaire administration
Study: NCT04115293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zilucoplan (RA101495)
Description: Daily subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily subcutaneous (SC) injection
Study: NCT03613597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide plus lobaplatin
Description: Thoracic intensity modulated radiation therapy (IMRT) + etoposide plus lobaplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide plus cisplatin
Description: Thoracic intensity modulated radiation therapy (IMRT) + etoposide plus Cisplatin
Study: NCT04541160

Intervention type: DIAGNOSTIC_TEST
Intervention: CR
Description: Lung imaging evaluation performed with CR

Intervention type: DIAGNOSTIC_TEST
Intervention: ULDCT
Description: Lung imaging evaluation performed with ULDCT
Study: NCT04063267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E cigarettes
Description: Participants will be encouraged to substitute e-cigarettes for combustible cigarettes in order to reduce nicotine withdrawal symptoms

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy
Description: Nicotine patches and gum to last them the first week based on their baseline recorded smoking. Participants will be advised to use both a 21 mg nicotine patch and 4 mg nicotine for cravings.
Study: NCT02769676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3-week visit
Description: The intervention will be an additional visit to the usual postpartum care provider at 3-weeks postpartum.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Participants in the usual care arm will receive no additional interventions.
Study: NCT02753218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 32731
Study: NCT00504985

Intervention type: BEHAVIORAL
Intervention: Surveys
Description: 2 surveys, taking about 10-15 minutes each, during Emergency Center visit
Study: NCT03880604

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Triple tourniquets
Description: A number 1 polyglactin suture was tied around the cervix to occlude the uterine arteries, and polythene tourniquets were tied around the infundibulopelvic ligament to obstruct the ovarian vessels

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Triple tourniquets
Description: A number 1 polyglactin suture was tied around the cervix to occlude the uterine arteries, and polythene tourniquets were tied around the infundibulopelvic ligament to obstruct the ovarian vessels

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TA
Description: 1-gram tranexamic acid (10 ml) in 100 ml saline infusion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo to TA
Description: placebo to 1-gram tranexamic acid (10 ml) in 100 ml saline infusion
Study: NCT01553032

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erbitux®
Description: 400mg/m2 initial dose, followed by weekly doses of 250mg/m2 Treatment duration: 7-8 weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Fractionated Radiotherapy
Description: 30-35 fractions of radiotherapy (6-7 weeks)
Study: NCT02363283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glembatumumab Vedotin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01444352

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine Formulation 1
Description: 0.5 mL, Intramuscular (Low dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine Formulation 2
Description: 0.5 mL, Intramuscular (Middle dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine Formulation 3
Description: 0.5 mL, Intramuscular (High dose)
Study: NCT02363283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01444352

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL, Intramuscular
Study: NCT02030054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Patients were randomly assigned to atorvastatin (40 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Patients were randomly assigned to atorvastatin (40 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Patients were randomly assigned to rosuvastatin (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
Study: NCT02375711

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: A blood sample of 35 ml is achieved at 1 month to evaluate the anti-HBV cell response. Two other blood samples of 10 ml are scheduled 3 and 6 months after vaccination to assess humoral response to HBV vaccination.
Study: NCT04216550

Intervention type: DRUG
Intervention: Apatinib
Description: Apatinib 0.5g orally daily until the untolerable toxicities, disease progression or death
Study: NCT04148755

Intervention type: PROCEDURE
Intervention: Endoscopic ultrasound guided fine needle aspirate
Description: All patients are going to have an EUS guided elastography with FNA of solid pancreatic lesions

Intervention type: PROCEDURE
Intervention: Endoscopic ultrasound guided fine needle aspirate
Description: All patients are going to have an EUS guided elastography with FNA of solid pancreatic lesions
Study: NCT01882829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dextromethorphan/quinidine
Description: up to 45/10 mg every 12 hours in patients with TRD with a short 7 day tapering period in which subjects are tapered off 45/10 mg dose from twice a day to once daily for an additional 7 days at post 8-week treatment period to minimize the potential for discontinuation effects
Study: NCT01100580

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low salt diet
Description: Daily salt intake less than 4 g/day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: water therapy
Description: abundant intake of water with a low mineral and low sodium content (at least 2 litres in winter and 3 in summer).
Study: NCT02030054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Patients were randomly assigned to rosuvastatin (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
Study: NCT05542134

Intervention type: DIAGNOSTIC_TEST
Intervention: P2Y12 Platelet Aggregation Inhibitor
Description: Verify now PRU test
Study: NCT03453515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEART
Description: Interactive web-based intervention with five modules: motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Growing Minds
Description: Interactive web-based intervention with five modules: mindsets introduction, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and integrative summary.
Study: NCT02673060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBC-11
Description: 0.5 mg/kg-10 mg/kg , IV (in the vein) on day 1-5 of each 28 day cycle. Number of cycles: 2, in case of partial metabolic reaction or stable metabolic reaction - up to 4.
Study: NCT02571881

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caesarean section
Description: After caesarean section oxycodone or oxycodone-naloxone prolonged release tablet twice a day is started for pain medication

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caesarean section
Description: After caesarean section oxycodone or oxycodone-naloxone prolonged release tablet twice a day is started for pain medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxycodone-naloxone
Study: NCT02500966

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DUDA device
Description: Insertion DUDA device

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LEEP
Description: Loop Electrosurgical Excision Procedure
Study: NCT05542134

Intervention type: DIAGNOSTIC_TEST
Intervention: P2Y12 Platelet Aggregation Inhibitor
Description: Verify now PRU test

Intervention type: DIAGNOSTIC_TEST
Intervention: P2Y12 Platelet Aggregation Inhibitor
Description: Verify now PRU test